The ABC revealed recently that over 3,100 prescriptions of medicinal cannabis have been approved by the Therapeutic Goods Administration (TGA) since March 2018.
More people are becoming aware of the benefits of medicinal marijuana and are seeking out the natural medicine from their doctors.
Helping these people are the Cannabis Doctors Australia, or CDA, who seek to aid individuals on their journey to being prescribed cannabis across Australasia.
CDA clinics are a doctor led company which sees patients first through it's own clinics, and also through Telehealth throughout Australia. Since launching in 2018, CDA have successfully processed over 1700 patient approvals, as well as over 2000 medical cannabis prescriptions for over 1100 patients.
CDA clinics fall under the umbrella company of CDA Health, who house CDA clinics in Australia and New Zealand, as well as Burleigh Heads Cannabis, an importer and wholesaler of medicinal cannabis, and Healthy not High, a company which specialises in hemp-based healthfoods.
Most recently, CDA clinics ran Australia's very first equity crowdfunding campaign for a medical cannabis company, allowing everyday Australian's to own a piece of CDA. The campaign was in search for funds to expand CDA's operations in order to up manufacturing capabilities and lower costs for patients.
We spoke with both CDA and their crowdfunding platform PledgeMe to discuss the future of medical cannabis in Australia and where CDA is headed.
The Crowdfunding Process
Cannabis Doctors Australia's crowdfunding attempt was the first in the history of an Australian Cannabis company, and reached over $1.5 million AUD by the end of the campaign.
We asked Anna Guenther, the 'Chief Bubble-Blower' of PledgeMe (Anna refuses the title of CEO) about what it was like to raise funds for CDA clinics.
Guenther stated to us that "after working closely with CDA we feel they are well positioned to build a lasting company while helping patients get access to medication which is the largest bottleneck the industry is facing at the moment (only 6,000 people currently have access and there are estimates over 200,000 are using the black market for medical cannabis)."
Crowdfunding can be not only a practical way to raise capital, but also a good litmus test for the general enthusiasm surrounding any given company. And now, thanks to CDA and other cannabis companies who've turned to crowdfunding, we're seeing that enthusiasm around cannabis is high.
Despite cannabis crowdfunding being new in Australia, PledgeMe were no strangers to the challenge. The company had previously worked with a New Zealand based company Waiapu Investments in order to similarly raise money towards their cannabis operations.
"In New Zealand, we previously assisted Waiapu investments who raised $2,000,000 in just 10 minutes after opening to the public. The money was raised for the company to build a pharmaceuticals processing facility and plant growing operations in Ruatorea and to carry out phase one clinical trials for a New Zealand made medical cannabis product."
Cannabis is buzzing with hype and we're seeing it in the results of these crowdfunding companies. With their newly acquired capital, the Director of Operations at CDA Health, Guy Headley told us the company's plans to implement their 3 phase business strategy to expand their business into Australia's first "plant to patient" model.
"While a lot of companies have started at the capital intensive cultivation stage, we have reverse engineered the model to focus on patients and finished products – a strategy that has now proven to be incredibly valuable to those cultivators/manufacturers who are not legally able to approach patients directly."
"With the successful capital we have just raised, it means we are able to now move into phase 2 of our plan which focuses on the next goal of 10,000 patients through our unique doctor/clinic program. It also enables us to develop an integral technology platform that will be able to cater to volume while not compromising our core services standards. Finally we will continue the process of obtaining our manufacturing license and capabilities. At this point we believe we will be in a very strong position in the Australasian market to look for that next step."
The Current Australian Medicinal Cannabis Landscape
When asked about the current landscape of the medicinal cannabis industry, Headley said there was a lot to be desired:
"Daily we see patients struggling to get a referral from their regular GP who hasn't educated themselves on the updated legislation and/or how the endocannabinoid system works in the human body. We have had to step in on a number of occasions where the patients doctor has gone against their duty of care to assist with alternative legal treatments to find another doctor in their local area who has done the referral to us."
Given the infancy of Australia's medical marijuana industry, many doctors simply don't know enough about cannabis to feel comfortable with prescribing it. On top of this, sourcing cannabis can be difficult, which leads to a surge in prices and sometimes an unreliable supply.
This is especially pertinent as cannabis leaders such as Canada have faced supply shortages with their retail cannabis stores given the enormous demand for the plant. If a patient is prescribed medicinal cannabis, especially in cases such as epilepsy or cancer treatment, it's imperative there's a constant stream of supply. Otherwise, you're better off having a more traditional pharmaceutical product.
"Our 3 main factors when sourcing products is quality, price and reliability of supply. While the first 2 are obvious, the third is one that is critical for both patients and doctors to ensure a continuity of care. There is currently a short, unreliable local supply with many cultivators only producing a small amount in order to either fulfil an investment milestone or to export overseas. Until there is an affordable, constant local supply we will continue to offset our Australian suppliers with international ones."
Alongside ensuring a constant stream of supply, CDA prides themselves on a very affordable, high-grade product.
"We are seeing that a majority of those who need medicinal cannabis are either being highly overcharged or having to miss out completely. Our company Burleigh Heads Cannabis currently has the most affordable CBD oil on the market in Australia and that is what our doctors prescribe over 70% of the time to our patients. With very good results the majority of the time."
"Depending on the exact product and dosage that a specific patient is prescribed costs in the average range of $4-$10. An important note for patients who are comparing product costs is to use the ratio of active ingredient, for example CBD, to whatever it is mixed with.
"There are some companies who offer larger bottles, however the concentration is lower so that the patient would need to take more to get the same amount of active product. (e.g. 6 drops vs 1 drop). We recommend a higher concentrated smaller bottle rather than a diluted larger bottle. Currently, we have the most affordable CBD product on the market in Australia and have it as a priority to bring costs down across the board for every product."
Where the Industry is Headed
CDA clinics has experienced sharp growth since it's conception, treating a growing range of conditions with their CBD products.
"While 80% of our patients are approved and prescribed for some form of chronic pain, we have now approved over 50 conditions including palliative care, cancer pain and related symptoms, Anxiety, insomnia, PTSD, Epilepsy and seizure management."
"Everyday is another success story. While medical cannabis does not work for everyone, the majority of our patients have found it beneficial."
– Guy Headley, Director of Operations at CDA Health
Market intelligence firm Prohibition Partners pegs the medical cannabis industry at $17.7 million annually, set to reach $3 billion by 2028. The plant is used as a treatment for a range of issues and between August and September alone, the TGA approved 469 applications for the drug under the Special Access Scheme.
CDA clinics are experiencing much of this growth as one of Australia's premiere methods of sourcing medical cannabis.
Part of the surge in medical cannabis, Headley believes is due to the desire for patients to switch to more natural medicines.
"For a number of our patients it's their number one goal for them to live better, less restrictive lives that don't include drugs that have done more harm than good to them over years and years. We've even had people so eager to get off harmful drugs that they have stopped all opioid medications the day that they pick up their Medical Cannabis product from the pharmacy. While this is not a feasible way to reduce the use of them for the majority of people, it goes to show the abrupt shift in a growing populations mindset about being able to control what they put in their body."
As we've mentioned many times here on The Green Fund, Australia's medicinal cannabis industry is only in its infancy, and is destined to grow phenomenally in the coming decade. Cannabis Doctors Australia have positioned themselves very nicely into this sector and things are only shaping up to improve.
Their acquisition of capital gives CDA a chance to continue pushing their growth and dominance of the Australian medicinal cannabis industry, which will undoubtedly be very lucrative in the years to come.
And as the company enters the second phase of their 3-pronged plan to dominate the medical cannabis industry, access and affordability of cannabis-based medicines will only improve. Couple this with the fact that people are seeking out more natural alternatives for medicine and wellness products, and its clear that the future is looking green.
& Keep Up to Date
Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!